Ozone Improved Bone Dynamic of Female Rats Using Zoledronate
Tiburtino J de Lima Neto1, Leonardo Alan Delanora1, Maria Eloise de Sá Simon1
1Department of Diagnosis and Surgery, School of Dentistry, São Paulo State University (UNESP), Araçatuba, Brazil.
This study investigated whether ozone therapy could enhance the bone-strengthening effects of zoledronic acid in female rats that had undergone ovariectomy. Researchers found that combining these treatments improved bone volume and vitality compared to using the medication alone.
Area of Science:
- Bone tissue engineering and ozone therapy research
- Pharmacology and metabolic bone disease studies
Background:
No prior work had fully resolved how ozone gas influences skeletal remodeling in models with estrogen deficiency. That uncertainty drove the need for investigating combined therapeutic strategies for bone health. Prior research has shown that zoledronic acid effectively inhibits bone resorption in osteoporotic conditions. However, the long-term impact of this medication on bone tissue vitality remains a subject of ongoing debate. This gap motivated researchers to explore whether supplemental gas therapies might provide added benefits. Previous studies often focused on single-agent interventions rather than synergistic pharmacological approaches. Understanding the interaction between oxidative agents and bisphosphonates is essential for advancing regenerative medicine. This investigation addresses the potential for ozone to modulate skeletal responses in compromised physiological states.
Purpose Of The Study:
The aim of this study was to analyze the effect of ozone therapy on the dynamics of bone tissue in ovariectomized rats treated with zoledronic acid. Researchers sought to determine if this gas could enhance the therapeutic outcomes of standard bisphosphonate treatments. This investigation addressed the challenge of maintaining skeletal integrity following estrogen depletion. The team examined whether oxidative agents might provide a synergistic benefit for bone mass preservation. By comparing various treatment combinations, the authors intended to clarify the role of ozone in bone metabolism. No prior work had established the specific impact of this combined regimen on structural vitality. This study was motivated by the need to find adjunctive therapies for metabolic bone disorders. The researchers designed the experiment to evaluate both biomechanical and cellular responses in the femoral head and spine.
Main Methods:
The researchers employed a longitudinal design involving one hundred and ten female Wistar rats. All subjects underwent bilateral ovariectomy to simulate postmenopausal bone loss. Review approach involved dividing the animals into distinct cohorts after a three-month stabilization period. The team administered zoledronic acid or saline solutions for twenty-eight days. Subsequently, they introduced intraperitoneal ozone injections every forty-eight hours to specific subgroups. Investigators utilized high-resolution imaging to evaluate skeletal architecture at multiple time points. They performed mechanical stress testing on femoral samples to determine structural integrity. Finally, the group applied statistical modeling with a significance threshold set at point zero five.
Main Results:
The strongest finding indicates that bone volume percentage increased significantly in the femoral head of the combined treatment group. Osteocyte and inflammatory cell counts were also upregulated in this specific anatomical region. Biomechanical testing showed that the modulus of elasticity was statistically similar between the zoledronic acid and combined therapy groups. However, a significant difference emerged when comparing the saline and saline-plus-ozone cohorts. Fluorescent marker analysis revealed that positive areas for calcein and alizarin were higher in groups receiving the bisphosphonate. These results suggest that ozone therapy contributes to the maintenance of bone mass. The data confirm that the combined protocol restores vitality within the bone tissue. Overall, the findings demonstrate a positive interaction between the two therapeutic agents.
Conclusions:
The authors propose that ozone therapy exerts a positive synergistic influence when combined with zoledronic acid. This combination appears to support the preservation of skeletal mass in estrogen-deficient models. The researchers suggest that these interventions may restore vitality within the bone tissue matrix. Findings indicate that the combined treatment protocol enhances specific structural parameters in the femoral head. The study highlights that elasticity modulus outcomes vary depending on the presence of the bisphosphonate. Authors note that the observed effects on bone formation markers are consistent across the treated cohorts. These results provide a basis for further exploration into oxidative therapies for skeletal recovery. The evidence points toward a potential role for ozone in optimizing standard pharmacological bone treatments.
Frequently Asked Questions
The researchers propose that the combined administration of ozone and zoledronic acid creates a synergistic effect. This interaction enhances bone volume percentage and increases the counts of osteocytes and inflammatory cells within the femoral head region compared to using the medication alone.
The study utilized micro-computed tomography to characterize bone architecture. Additionally, researchers performed biomechanical testing on the femoral neck, employed laser confocal microscopy, and conducted histological counts of inflammatory cells and osteocytes to evaluate tissue health.
The femoral head and spine were necessary regions for analysis because they are common sites for bone density loss. Examining these specific areas allowed the researchers to observe structural characterization and quantify neoformed bone areas effectively.
The researchers used calcein and alizarin labeling to measure bone formation. These fluorescent markers allowed the team to quantify positive areas, which were found to be higher in groups receiving zoledronic acid compared to those receiving only saline.
The biomechanical analysis measured the modulus of elasticity. The researchers observed that this value remained similar between the zoledronic acid and the combined ozone group, whereas significant differences appeared when comparing the saline and saline-plus-ozone groups.
The authors propose that this therapeutic approach could assist in the maintenance of bone mass. They suggest that the combination of these two agents helps restore bone tissue vitality in subjects experiencing estrogen deficiency.
Related Concept Videos
01:29Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:40Bone Remodeling